Open AccessReal-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India
Author(s) -
Shashank Joshi,
Agam Vora,
K Venugopal,
Pramod Dadhich,
Anil Daxini,
Sagar Bhagat,
Saiprasad Patil,
Hanmant Barkate
Publication year - 2022
Publication title -
pragmatic and observational research
Language(s) - English
Resource type - Journals
ISSN - 1179-7266
DOI - 10.2147/por.s364066
Subject(s) - favipiravir , medicine , myalgia , adverse effect , population , covid-19 , disease , infectious disease (medical specialty) , environmental health
Favipiravir, an RNA-dependent RNA polymerase inhibitor (RdRp), is a broad-spectrum oral antiviral agent approved in India under emergency use authorization, for the treatment of mild-to-moderate coronavirus disease (COVID-19). The present study was planned to evaluate the effectiveness and safety of favipiravir in real-world clinical practice.